ABSTRACT
Background: Damaging of the lung function in patients with cystic fibrosis is the most frequent cause of death in these patients. Recently, Burkholderia cepacia has been emerged as an important opportunistic pathogen in these patients; because of its increased isolation from patients with cystic fibrosis since late1970s, the capacity for spread of infection among the cystic fibrosis patient community, its role in damaging lung functions, and its innate multiantibiotic resistance. These different aspects make isolation of Burkholderia cepacia an important task in cystic fibrosis health care settings
Materials and Methods: We examined the capacity of Burkholderia cepacia selective agar [BCSA] as a medium for primary isolation of Burkholderia cepacia samples. Biochemical tests were used to confirm the identification
Results: Burkholderia cepacia strains were isolated from 6 out of 53 respiratory samples as confirmed with biochemical tests
Conclusion: Results of the present study suggest that BCSA can be used as a selective medium with high specificity for primary isolation and identification of Burkholderia cepacia complex bacteria
ABSTRACT
A sensitive high performance liquid chromathography [HPLC] analytical procedure was developed for the quantitive determination of trimethoprim [TM] and sulphamethoxazole [SM] in commercial dosage forms. C18 analytical column [stainless steel, 25 cm X 4.6 mm i.d.] was packed with 5-micro m particles of the reversed phase material and used for assays. Mobile phase containing 0.025 M sodium phosphate as aqueous phase and acetonitrile with 0.4% triethylamine as organic phase. The drugs were quantified at flow-rate of 1.2 ml/min, with ultraviolet detection at 260 nm. The minimum detectable quantities in assays were 100 ng/ml for SM and 75 ng/ml for TM. The method is well suited to routine application and adequate sensitivity with precision